| Name | PI3K/Akt/mTOR-IN-2 |
| Description | PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells. |
| In vitro | PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 h) demonstrates significant anti-cancer efficacy, with IC50 values between 2.29 and 24.63 μM, notably 2.29 μM in MDA-MB-231 cells.[1] It induces growth inhibition in MDA-MB-231 cells by causing cell cycle arrest at G0/G1 (1, 2, and 4 μM; 24 h), elicits dose- and time-dependent apoptosis (1, 2, and 4 μM; 24, 48, and 72 h), increases Bax expression and decreases Bcl-2 expression (1, 2, and 4 μM; 48 h), and triggers mitochondria-dependent apoptosis by disrupting mitochondrial membrane potential, increasing ROS, reducing GSH levels, and elevating intracellular Ca2+ (1, 2, and 4 μM; 24 h).[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (192.79 mM), Sonication is recommended.
|
| Keywords | PI3K | mTOR | Apoptosis | Akt |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Hematonosis Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Active Compound Library |
United States
